NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting...

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “As we work toward our goal of launching multiple products...

First Quarter Fiscal 2026 Revenue of $19.5 Million,Reflecting a 10% Increase Year Over Year LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) — Daily Journal Corporation (Nasdaq: DJCO), a publishing and technology company, today announced financial results for the three months ended December 31, 2025. Total consolidated revenue for the quarter was $19.5 million, representing a 10% increase from the $17.7 million reported in the prior-year quarter, driven primarily by growth at Journal Technologies. “Journal Technologies continued to deliver solid year-over-year growth in the first quarter of fiscal 2026, driven by higher e-filing and other public service fees and recurring license and maintenance revenues,” said Steven Myhill-Jones, Chairman of the Board and Chief Executive Officer of Daily Journal Corporation. “We remain focused on...

All of the amounts disclosed in this press release are in U.S. dollars unless otherwise noted TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) — Enlight Renewable Energy (NASDAQ: ENLT, TASE: ENLT) today reported financial results for the fourth quarter of 2025 ending December 31, 2025. Registration links for the Company’s earnings English and Hebrew conference call and webcasts can be found at the end of this earnings release.The entire suite of the Company’s 4Q25 financial results can be found on our IR website at https://enlightenergy.co.il/data/financial-reports/Financial Highlights 12 months ending December 31, 2025Revenues and income of $582m, up 46% year over year Net income of $161m, up 142% year over year Adjusted EBITDA1 of $438m, up 51% year over year Cash flow from Operating activities2 of $283m, up 11% year...

Falcon Oil & Gas Ltd. (“Falcon”) Notice of Cancellation of Admission to Trading on AIM 17 February 2026 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) announces, in accordance with applicable AIM Rules, that the admission of Falcon’s common shares to trading on AIM will be cancelled (the “AIM Cancellation”) following completion of Falcon’s previously announced transaction (the “Transaction”) with Tamboran Resources Corporation (“Tamboran”). Pursuant to the terms of an arrangement agreement and plan of arrangement governing the Transaction, (a) Tamboran will (i) issue to Falcon 6,537,503 shares of Tamboran common stock (the “Stock Issuance”) and (ii) pay to Falcon $23,663,080 in cash and (b) Falcon shareholders (other than dissenting Falcon shareholders or Falcon shareholders subject to sanctions) will then be entitled to...

15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total revenue and operating profit Conference call and webcast today at 4 p.m. (CET)Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 17, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharma company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2025. David Veitch, Chief Executive Officer, stated: “A few years ago, we set out to transform Basilea by focusing on treatments for severe bacterial and fungal infections. Since then, Basilea has become a profitable company, with consistent...

Lerøy Seafood Group ASA will present its results for Q4 2025 on 24 Februar 2026 at Continental Hotel, Stortingsgata 24/26 in Oslo at 08:00 CET. The presentation will be held in Norwegian followed by a Q&A session. Delicious seafood will be served from 07:45 CET. You may alternatively follow the Norwegian presentation and submit questions through a live broadcast available on https://www.leroyseafood.com/no/investor/. The quarterly report and presentation will be published at 06:30 CET. A recording of the presentation in English will be available from 12:00 CET on http://www.leroyseafood.com/en/investor This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.  

Total Revenue of $1.4 billion in 4Q25 and $5.4 billion in FY25 Adjusted EBITDAR Margin of 35% in 4Q25 and 31% in FY25, highest on record Operating Margin of 21% in 4Q25 and 17% in FY25 Premium revenue at 42% in 4Q25 and FY25MEXICO CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended December 31, 2025 (“4Q25”) and twelve months ended December 31, 2025 (“FY25”) and as of December 31, 2025. The unaudited consolidated financial results set forth below are subject to revision based upon the completion of our annual financial closing process, and other developments arising between now and the time this financial closing process is finalized. These results are based on information...

Company Hosting New York Investor Day Meeting February 17th HARTSVILLE, S.C., Feb. 16, 2026 (GLOBE NEWSWIRE) — Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today reported financial results for the fourth quarter and full year ended December 31, 2025. Summary:Grew fourth quarter net sales to $1.8 billion, up 29.7% from the prior-year quarter, primarily from acquisition activity Reported fourth quarter U.S. generally accepted accounting principles (“GAAP”) net income attributable to Sonoco of $332.2 million, up from a loss of $(43.0) million in the same period in 2024, GAAP operating profit of $520.2 million, up from $56.1 million in the same period in 2024, and diluted earnings/(loss) per share (“EPS”) attributable to Sonoco of $3.33, up from $(0.44) in the...

Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will...